Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?
Key PointsNovo’s third-quarter update was strong, largely due to its oral weight-loss pill.
Novo Nordisk has delivered strong financial results, potentially signaling a turnaround for investors. The Danish pharmaceutical giant's latest quarterly earnings report saw a 6% increase in total net sales, totaling 79.2 billion DKK ($11.9 billion), compared to the same period last year. Despite some underperformance from key growth drivers like Ozempic and Wegovy, other medicines helped offset this decline.
Notably, oral Wegovy, the first oral GLP-1 treatment, surpassed three million prescriptions by June, with 80% of users being first-time GLP-1 patients. This launch has proven lucrative, generating 5.4 billion DKK ($810 million) in revenue in the third quarter. Novo's total net sales beat analyst estimates, and the company raised its guidance for the fiscal year 2026, predicting flat revenue year-over-year.
Several factors could further boost Novo's performance, including the potential approval of oral Wegovy in additional countries, label expansions, and new product launches like CagriSema and promising pipeline candidates like zenagamtide. Despite some clinical setbacks, Novo's recent performance suggests a promising comeback on the horizon.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
